Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancerTomohiro Sakakibara, T. Nukiwa, Takashi Ishida et al.|Annals of Oncology|2009Cited by 36
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601Shunichi Sugawara, Toshihiro Nukiwa, Makoto Maemondo et al.|Lung Cancer|2013Cited by 28
Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801Makoto Maemondo, Toshihiro Nukiwa, Akira Inoue et al.|The Oncologist|2014Cited by 21
A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703Nobumichi Matsubara, Toshihiro Nukiwa, Makoto Maemondo et al.|Respiratory Investigation|2012Cited by 12
Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.Yosuke Kawashima, Toshihiro Nukiwa, Akira Inoue et al.|Journal of Clinical Oncology|2013Cited by 6